These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 31267009

  • 1. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
    Nik ME, Malaekeh-Nikouei B, Amin M, Hatamipour M, Teymouri M, Sadeghnia HR, Iranshahi M, Jaafari MR.
    Sci Rep; 2019 Jul 02; 9(1):9527. PubMed ID: 31267009
    [Abstract] [Full Text] [Related]

  • 2. The effect of RGD-targeted and non-targeted liposomal Galbanic acid on the therapeutic efficacy of pegylated liposomal doxorubicin: From liposomal preparation to in-vivo studies.
    Nik ME, Jaafari MR, Mashreghi M, Nikoofal-Sahlabadi S, Amin M, Sadeghnia HR, Iranshahi M, Navashenaq JG, Malaekeh-Nikouei B.
    Int J Pharm; 2021 Jul 15; 604():120710. PubMed ID: 34019972
    [Abstract] [Full Text] [Related]

  • 3. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
    Amin M, Badiee A, Jaafari MR.
    Int J Pharm; 2013 Dec 31; 458(2):324-33. PubMed ID: 24148663
    [Abstract] [Full Text] [Related]

  • 4. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
    Mirhadi E, Askarizadeh A, Farhoudi L, Mashreghi M, Behboodifar S, Alavizadeh SH, Arabi L, Jaafari MR.
    Chem Phys Lipids; 2024 Jul 31; 261():105396. PubMed ID: 38621603
    [Abstract] [Full Text] [Related]

  • 5. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M, Farzaneh H, Badiee A, Golmohammadzadeh S, Sadri K, Jaafari MR.
    Eur J Pharm Sci; 2015 Dec 01; 80():66-73. PubMed ID: 26299343
    [Abstract] [Full Text] [Related]

  • 6. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
    Biabangard A, Asoodeh A, Jaafari MR, Mashreghi M.
    Expert Opin Drug Deliv; 2022 Dec 01; 19(12):1710-1724. PubMed ID: 36373415
    [Abstract] [Full Text] [Related]

  • 7. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
    Mashreghi M, Faal Maleki M, Karimi M, Kalalinia F, Badiee A, Jaafari MR.
    J Drug Target; 2021 Jul 01; 29(6):617-630. PubMed ID: 33393376
    [Abstract] [Full Text] [Related]

  • 8. Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
    Wu SK, Chiang CF, Hsu YH, Lin TH, Liou HC, Fu WM, Lin WL.
    Int J Nanomedicine; 2014 Jul 01; 9():4485-94. PubMed ID: 25278753
    [Abstract] [Full Text] [Related]

  • 9. Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor.
    Amiri Darban S, Nikoofal-Sahlabadi S, Amiri N, Kiamanesh N, Mehrabian A, Zendehbad B, Gholizadeh Z, Jaafari MR.
    Colloids Surf B Biointerfaces; 2018 Apr 01; 164():107-115. PubMed ID: 29413587
    [Abstract] [Full Text] [Related]

  • 10. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M, Nikoofal-Sahlabadi S, Nikpoor AR, Ghaffari S, Attar H, Mashreghi M, Jaafari MR.
    Anticancer Agents Med Chem; 2020 Apr 01; 20(6):700-708. PubMed ID: 31893998
    [Abstract] [Full Text] [Related]

  • 11. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L, Badiee A, Mosaffa F, Jaafari MR.
    J Control Release; 2015 Dec 28; 220(Pt A):275-286. PubMed ID: 26518722
    [Abstract] [Full Text] [Related]

  • 12. Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma.
    Shahraki N, Mehrabian A, Amiri-Darban S, Moosavian SA, Jaafari MR.
    Colloids Surf B Biointerfaces; 2021 Apr 28; 200():111589. PubMed ID: 33545570
    [Abstract] [Full Text] [Related]

  • 13. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M, Mansourian M, Koning GA, Badiee A, Jaafari MR, Ten Hagen TLM.
    J Control Release; 2015 Dec 28; 220(Pt A):308-315. PubMed ID: 26526970
    [Abstract] [Full Text] [Related]

  • 14. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M, Badiee A, Golmohammadzadeh S, Sadri K, Akhtari J, Mellat M, Nikpoor AR, Jaafari MR.
    Int J Pharm; 2016 Sep 10; 511(1):236-244. PubMed ID: 27363937
    [Abstract] [Full Text] [Related]

  • 15. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA, Abnous K, Badiee A, Jaafari MR.
    Colloids Surf B Biointerfaces; 2016 Mar 01; 139():228-36. PubMed ID: 26722819
    [Abstract] [Full Text] [Related]

  • 16. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X, Widjaya AS, Liu J, Liu X, Long Z, Jiang Y.
    Acta Biomater; 2020 Apr 01; 106():301-313. PubMed ID: 32081779
    [Abstract] [Full Text] [Related]

  • 17. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M, Abnous K, Mohammadi M, Hadizadeh F, Sadeghi F, Taghavi S, Jaafari MR, Ramezani M.
    J Control Release; 2017 Oct 28; 264():228-236. PubMed ID: 28844758
    [Abstract] [Full Text] [Related]

  • 18. AR13 peptide-conjugated liposomes improve the antitumor efficacy of doxorubicin in mice bearing C26 colon carcinoma; in silico, in vitro, and in vivo study.
    Biabangard A, Asoodeh A, Jaafari MR, Moosavi Baigi F.
    Toxicol Appl Pharmacol; 2023 May 01; 466():116470. PubMed ID: 36933622
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic efficacy of combining pegylated liposomal doxorubicin and radiofrequency (RF) ablation: comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nano-liposomes.
    Andriyanov AV, Koren E, Barenholz Y, Goldberg SN.
    PLoS One; 2014 May 01; 9(5):e92555. PubMed ID: 24786533
    [Abstract] [Full Text] [Related]

  • 20. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M, Gheybi F, Rezayat SM, Jaafari MR.
    Eur J Pharm Sci; 2016 Apr 30; 86():125-35. PubMed ID: 26972276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.